Publication Ethics & Malpractice Statement

Publication Ethics and Malpractice Statement

Jurnal Ilmiah Medicamento (JINTO) is a peer-reviewed electronic scientific journal published by the Faculty of Pharmacy, Universitas Mahasaraswati Denpasar, since 2015. JINTO is committed to upholding the highest standards of publication ethics and takes all reasonable measures to prevent publication malpractice in any form.

The Editorial Board of JINTO does not tolerate unethical practices, including plagiarism, data fabrication, data falsification, duplicate publication, or other forms of scientific misconduct. All parties involved in the publication process—authors, reviewers, editors, and the publisher—are required to adhere to ethical standards based on the Committee on Publication Ethics (COPE) Code of Conduct and Best Practice Guidelines for Journal Editors. These guidelines are intended to ensure the integrity of the scholarly record and the transparency of the publication process.

1. Publication and Peer-Review Process

All manuscripts submitted to JINTO undergo a rigorous editorial screening followed by a double-blind peer-review process conducted by independent reviewers with relevant expertise.

Manuscripts are evaluated based on:

  • Relevance to the journal’s scope
  • Scientific quality and methodological rigor
  • Originality and novelty
  • Clarity of presentation and language

Editorial decisions may include acceptance, acceptance with minor or major revisions, or rejection. Manuscripts rejected at any stage will not be reconsidered. Submission of a revised manuscript does not guarantee acceptance. Manuscripts must comply with applicable legal requirements concerning plagiarism, defamation, and copyright infringement. Research findings may not be published in more than one journal.

2. Authors’ Responsibilities

Authors submitting manuscripts to JINTO must certify that:

  1. The manuscript is an original work and has not been previously published, in whole or in part, in any language.
  2. The manuscript is not under consideration by another journal.
  3. All data presented are accurate, authentic, and obtained ethically.
  4. The manuscript is free from scientific misconduct, including plagiarism and self-plagiarism.
  5. The subject matter falls within the journal’s scope, which includes:
  • Pharmacology and Toxicology
  • Clinical and Community Pharmacy
  • Pharmaceutical Chemistry
  • Pharmaceutical Biology
  • Pharmaceutical Technology
  • Pharmaceutical Microbiology and Biotechnology
  • Regulatory Affairs and Pharmacy Marketing Research
  • Alternative Medicine

Authors must participate constructively in the peer-review process, ensure that all listed authors have made significant contributions to the research, properly acknowledge all sources, and provide appropriate citations. Authors are required to disclose any conflicts of interest and sources of funding.

If errors or inaccuracies are identified after publication, authors must promptly notify the editor and cooperate in issuing corrections or retractions. A signed originality and plagiarism-free statement is required upon submission.

3. Reviewers’ Responsibilities

  • Conduct reviews objectively, fairly, and within the agreed timeframe
  • Treat all manuscripts as confidential documents
  • Provide constructive feedback supported by clear arguments
  • Identify relevant literature not cited by the authors
  • Inform the editor of any substantial similarity between the manuscript and other published works
  • Decline review assignments in cases of conflict of interest

4. Editors’ Responsibilities

Editors are responsible for maintaining the integrity and quality of the journal. Editorial decisions are based solely on the manuscript’s academic merit, originality, clarity, and relevance to the journal’s scope.

  • Ensure a fair and unbiased peer-review process
  • Maintain reviewer and author confidentiality
  • Address allegations of misconduct following COPE guidelines
  • Publish corrections, retractions, or expressions of concern when necessary
  • Avoid conflicts of interest and ensure editorial independence

Editors shall not reverse editorial decisions without valid and substantiated reasons and must not reject manuscripts based solely on suspicion without evidence of misconduct.

5. Conflict of Interest

JINTO requires all authors to disclose any potential conflicts of interest that may influence the interpretation of their work. Conflicts may arise from financial, institutional, or personal relationships, including but not limited to patents, shareholdings, advisory roles, or board memberships.

If no conflict of interest exists, authors must explicitly state this upon submission. It is the responsibility of the corresponding author to ensure that all co-authors agree on the disclosure provided.

6. Handling of Publication Malpractice

Suspected cases of publication malpractice are handled in accordance with COPE procedures. Depending on the severity of the case, actions may include manuscript rejection, correction, retraction, notification of authors’ institutions, or other appropriate measures to preserve the integrity of the scientific record.

7. Direct Marketing and Communication Ethics

Jurnal Ilmiah Medicamento (JINTO) does not engage in aggressive, misleading, or unethical direct marketing practices. Promotion of the journal and calls for papers are conducted through official institutional channels, the journal’s website, and recognized academic networks. Any direct communication with authors or reviewers is carried out in a professional, ethical, and non-coercive manner. The journal does not guarantee manuscript acceptance, expedited publication, or preferential treatment. All submissions are subject to the same rigorous double-blind peer-review process.